Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6528247 | 1.00 | GRIA4 (0.48) | GRIA4TP53GRIA2KCNH2MTNR1A | |
| SCHEMBL6482324 | 0.89 | GRIA4 (0.46) | GRIA4TP53MTNR1AMTNR1BCA12 | |
| SCHEMBL6528249 | 0.84 | GRIA4 (0.67) | GRIA4GRIA2KCNH2MTNR1AMTNR1B | |
| SCHEMBL6475864 | 0.84 | GRIA4 (0.67) | GRIA4GRIA2KCNH2MTNR1AMTNR1B | |
| SCHEMBL6475297 | 0.84 | GRIA4 (0.48) | GRIA4MTNR1AMTNR1B | |
| SCHEMBL6482161 | 0.84 | MTNR1A (0.49) | GRIA4TP53MTNR1AMTNR1BKDM4E | |
| SCHEMBL6474393 | 0.84 | GRIA4 (0.43) | GRIA4TP53MTNR1AMTNR1BCA12 | |
| SCHEMBL6475311 | 0.83 | GRIA4 (0.47) | GRIA4TP53MTNR1AMTNR1BCA2 | |
| SCHEMBL6472661 | 0.83 | GRIA4 (0.42) | GRIA4MTNR1AMTNR1BCA2 | |
| SCHEMBL6475845 | 0.81 | GRIA4 (0.41) | GRIA4TP53MTNR1AMTNR1BCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911476-B2 | Sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-06-28 | — | — | US | claimed |
| US-20030225266-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-04 | — | — | US | claimed |
| EP-1265857-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001068592-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-09-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225266-A1 | Sulfonamide derivatives | GRIN2A, GRM2, GRIA2 | GRIA4 6/4885TP53 4836/4885GRIA2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.